Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Vincerx Pharma Inc (VINC)

NASDAQ
Currency in USD
Disclaimer
0.8967
-0.0333(-3.58%)
Closed
After Hours
0.7230-0.1737(-19.371%)
VINC Scorecard
Unusual Post-Market activity
Fair Value
Unlock Value
Day's Range
0.88000.9300
52 wk Range
0.61009.3722
Prev. Close
0.93
Open
0.92
Day's Range
0.88-0.93
52 wk Range
0.61-9.3722
Volume
235,271
Average Vol. (3m)
1,145,042
1-Year Change
-24.39%
Shares Outstanding
21,413,389
Fair Value
Unlock
Dividends Payment Streak
Unlock
Analysts
Technical
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell

People Also Watch

6.43
CADL
+6.28%
3.330
IZM
+18.51%
6.5100
BTTR
-4.55%
24.64
DXYZ
-7.02%
1.860
MDIA
-6.53%
How do you feel today about VINC?
Vote to see community's results!
or

Vincerx Pharma Inc Company Profile

Vincerx Pharma, Inc. is a clinical-stage biopharmaceutical company that is focused on the development and oncology knowledge to advance new therapies to address unmet medical needs for the treatment of cancer. The Company’s pipeline consists of enitociclib, which is in Phase I, and a modular bioconjugation platform, which includes a small molecule drug-conjugate (SMDC), VIP236, in Phase I, and preclinical next-generation antibody drug-conjugates, VIP943 and VIP924. Enitociclib, is a highly selective cyclin-dependent kinase 9 (CDK9) inhibitor. The Company's antibody-drug conjugate (ADC) platform includes VIP943 and VIP924, which are ADC compounds addressing known and oncology targets. The bioconjugation program also includes VIP236, which is a small molecule drug conjugate (SMDC) for solid tumors. VIP236 is a SMDC with a focus on treating patients with cancers.

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.